Acute Leukemia / Myelodysplastic syndrome (MDS)

AML

New Diagnosis
IRB#9141
Phase III Randomized CPX-351 versus Cytarabine and Daunorubicin in 60-75 years of age with untreated high risk AML

Relapsed/Refractory
IRB#7195
Phase II Kinase Inhibition using a Comprehensive In Vitro Inhibitor panel to select individualized targeted therapies

IRB#8495
Phase III Randomized using clofarabine in very High Risk stratum

ALL

New Diagnosis
IRB#4913
Phase II study involving HyperCVAD and Peg Asparaginase

Relapsed/Refractory
IRB#7195
Phase II Kinase Inhibition using a Comprehensive In Vitro Inhibitor panel to select individualized targeted therapies

IRB#3444
Using Nelarabine with standard treatment

CMML

IRB#8821
Expanded Access Program of Ponatinib (AP24534) for Refractory CML or Ph+ ALL

IRB#5669
Phase II study involving Vidaza for newly Diagnosed CMML 18 years and older

IRB#9141
Phase III Randomized CPX-351 versus Cytarabine and Daunorubicin in 60-75 years of age with untreated high risk AML